Biotek-snakken — Juli 2024
-
Og så lige en emission mere
dog kun med 5,5% rabat….. ACARIX: GÖR RIKTAD EMISSION 21 MLN KR
I dag kl. 06:04 ∙ Nyhetsbyrån Direkt
STOCKHOLM (Nyhetsbyrån Direkt) Acarix har beslutat om att genomföra en riktad nyemission av högst 60 miljoner aktier till en teckningskurs om 0:35 kronor per aktie, motsvarande en emissionslikvid om 21 miljoner kronor.Det framgår av ett pressmeddelande på onsdagskvällen.
Investerare i den riktade emissionen utgörs av ett antal USA-baserade så kallade Family Offic
-
? bedre end tradere, der smider aktien ved enhver stigning
Den holder egentlig kursen rimelig flot, ovenpå emissionen -
Nok fordi det er instituelle investorer der køber i emissionen….Giver en vis tro på fremtiden
-
Nu går det stærkt
14% op, efter at være faldet omkring 10% i åbningen Ikke for sarte nerver, men mine er nu køb og behold, og håbe på det HELT store gennembrud kommer. -
Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors:
-
"This strategic investment unlocks new product offerings for Genovis to both existing
and new customers and further paves the way for the expansion into new application
areas. Genovis will utilize its distribution network to market and sell SEQURNA’s
RNase inhibitors alongside its own catalogue of innovative tools for the
biopharmaceutical and research industries." -
Genovis: Strategic investment in developer of RNase inhibitors
(Redeye)
"Redeye comments on Genovis following the announcement of a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors. Similar to the market, we positively view the announcement."
"The market trades the share up a few percent on the announcement, our base case remains at SEK65."
-
XBRANE PROVIDES UPDATE ON TIMING OF RE-SUBMISSION OF BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE
" ... Should this submission be successful, this would result in a BsUFA date during the second quarter of 2025 assuming a standard 6 month review process and ongoing alignment with the FDA, as well as successful execution of remediation plans of the manufacturing partners."
-
Så begynder Cessatech at bevæge sig spændende på grafen - Kurs 7,0 er ramt i dag. Kan den holde sig på/over de 7 ved luk, burde det være stærkt støttesignal (se maj-sep 2022 perioden, hvor 7 var modstand). Fundamentalt hedder den markedslancering i disse uger i USA. Satser på en ganske positiv udvikling resten af året...og for den sags skyld også de næste par år...
-
BioArctic's Partner Eisai Says Leqembi Approved In Hong Kong For Alzheimer's Disease Treatment https://proinvestor.com/investornyt/1183677/bioarctics-partner-eisai-says-leqembi-approved-in-hong-kong-for-alzheimers-disease-treatment
-
ASCELIA PHARMA CARRIES OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 105 MILLION TO FULLY FINANCE THE NDA SUBMISSION FOR ORVIGLANCE
Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® – ASCELIA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, ...
(www.ascelia.com)
-
Ascelia: Proceeds with a SEK 105m rights issue of units
-
" ... We regard this initiative as positive. Ascelia will be in a strong position to negotiate terms with a US partner, and the funding will dramatically reduce the financial uncertainty in Ascelia. The proposed funding will also allow Ascelia to focus on securing FDA approval for Orviglance and securing a US commercial partner on favourable terms."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind